Holen Sie sich die Stockscreener-App
21.73
1.92%
0.41
Handel nachbörslich:
21.73
Schlusskurs vom Vortag:
$21.32
Offen:
$21.33
24-Stunden-Volumen:
5.83M
Relative Volume:
1.02
Marktkapitalisierung:
$10.85B
Einnahmen:
$4.72B
Nettoeinkommen (Verlust:
$-232.00M
KGV:
-46.60
EPS:
-0.4663
Netto-Cashflow:
$284.00M
1W Leistung:
+9.42%
1M Leistung:
-3.25%
6M Leistung:
-2.34%
1J Leistung:
+71.51%
1-Tages-Spanne:
$21.30
$22.05
1-Wochen-Bereich:
$19.40
$22.05
52-Wochen-Spanne:
$12.40
$27.72
Elanco Animal Health Inc Stock (ELAN) Company Profile
Firmenname
Elanco Animal Health Inc
Sektor
Telefon
877-352-6261
Adresse
450 ELANCO CIRCLE, INDIANAPOLIS
Compare ELAN vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELAN
Elanco Animal Health Inc
|
21.73 | 10.65B | 4.72B | -232.00M | 284.00M | -0.4663 |
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-15 | Eingeleitet | Citigroup | Buy |
| 2026-01-22 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-11-21 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2025-11-19 | Hochstufung | Argus | Hold → Buy |
| 2025-10-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-07-17 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-06-26 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2024-12-09 | Eingeleitet | UBS | Buy |
| 2024-12-02 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-09-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-01-05 | Hochstufung | Stifel | Hold → Buy |
| 2023-12-19 | Eingeleitet | Jefferies | Buy |
| 2023-12-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-07 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2023-04-20 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-08-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-16 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-07-21 | Herabstufung | Goldman | Buy → Sell |
| 2022-07-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-11-18 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-10-28 | Herabstufung | Stifel | Buy → Hold |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-06-15 | Hochstufung | Cleveland Research | Underperform → Neutral |
| 2021-05-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2021-05-11 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2021-04-15 | Eingeleitet | Stifel | Buy |
| 2021-03-22 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2021-02-26 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-09 | Herabstufung | Argus | Buy → Hold |
| 2020-11-09 | Herabstufung | Barclays | Overweight → Underweight |
| 2020-08-20 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-08-13 | Fortgesetzt | Credit Suisse | Neutral |
| 2020-08-04 | Fortgesetzt | Goldman | Buy |
| 2020-07-27 | Herabstufung | Cleveland Research | Neutral → Underperform |
| 2020-04-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-10 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-19 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-11-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-23 | Eingeleitet | Barclays | Overweight |
| 2019-08-26 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-08-15 | Hochstufung | UBS | Sell → Neutral |
| 2019-05-23 | Eingeleitet | Guggenheim | Neutral |
| 2019-03-18 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-03-13 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-02-12 | Eingeleitet | William Blair | Mkt Perform |
| 2019-01-23 | Eingeleitet | UBS | Sell |
| 2019-01-15 | Eingeleitet | Argus | Buy |
| 2018-10-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Elanco Animal Health Inc Aktie (ELAN) Neueste Nachrichten
Q1 Rundown: Elanco (NYSE:ELAN) Vs Other Pharmaceuticals Stocks - Yahoo Finance
Elanco Launches Befrena As New Dermatology Driver For Undervalued Shares - Yahoo Finance
Companion Animal Health Market is expected to Hit US$ 56.60 - openPR.com
Is Elanco Animal Health Inc (ELAN) Overvalued After 5.3% Rally? - GuruFocus
Elanco EVP Rajeev Modi buys $99,938 of company stock By Investing.com - Investing.com Nigeria
Elanco CEO Jeffrey Simmons buys $99,842 in company stock By Investing.com - Investing.com Nigeria
Elanco CEO Jeffrey Simmons buys $99,842 in company stock - Investing.com
Elanco EVP Rajeev Modi buys $99,938 of company stock - Investing.com
Elanco (NYSE: ELAN) officer Modi buys shares and receives deferred stock units - Stock Titan
Elanco (NYSE: ELAN) CEO adds shares and receives deferred units - Stock Titan
Elanco (NYSE: ELAN) CFO receives grant of deferred stock units as compensation - Stock Titan
Elanco Animal Health Launches Canine Dermatitis Drug Befrena - Moomoo
Elanco Animal Health (ELAN) 10K Form and Latest SEC Filings 2026 - MarketBeat
Elanco Animal Health’s SWOT analysis: stock outlook amid growth targets - Investing.com India
Elanco Animal Health’s SWOT analysis: stock outlook amid growth targets By Investing.com - Investing.com Nigeria
Elanco (ELAN) Launches New Canine Allergy Treatment Befrena - GuruFocus
Elanco launches canine dermatitis treatment Befrena in U.S. By Investing.com - Investing.com Canada
Elanco Launches Befrena™ (tirnovetmab), New Anti-IL-31 Monoclonal Antibody, a Breakthrough Addition to the $1.3 Billion U.S. Canine Dermatology Market - PR Newswire
Elanco Animal Health (ELAN) Stock Report: A Healthcare Stock with Nearly 50% Upside Potential - DirectorsTalk Interviews
Elanco Q1 2026 Earnings: Revenue $1.37B, EPS $0.40, Guidance RaisedNews and Statistics - IndexBox
5 Insightful Analyst Questions From Elanco’s Q1 Earnings Call - Yahoo Finance
Elanco Animal Health Inc (ELAN) Shares Fall 8.2% -- What GF Scor - GuruFocus
Elanco Animal Health Inc (ELAN) Shares Fall 8.2% -- What GF Score of 70 Tells Investors - GuruFocus
Elanco finalizes acquisition of AHV International - Feed Strategy
Morgan Stanley Maintains Elanco Animal Health(ELAN.US) With Hold Rating, Raises Target Price to $23 - Moomoo
Elanco to Participate in Investor Conferences - Intellectia AI
Elanco to Participate in Upcoming Investor Conferences - GuruFocus
Dodge & Cox holds 13.9% of Elanco (NYSE: ELAN) in 13G/A amendment - Stock Titan
How to listen in as Elanco execs talk to investors in May and June - Stock Titan
Elanco reaches $9.3M settlement with consumers over antitrust allegations involving flea and tick products - Indianapolis Business Journal
Elanco to pay $6.75M to settle antitrust allegations involving flea and tick products - Inside INdiana Business
Primecap Management reports 9.22% stake in Elanco (ELAN) - Stock Titan
Elanco On Hook For Bulk Of $9M Flea & Tick Meds Deal - Law360
Earnings call transcript: Elanco Q1 2026 beats forecasts with strong growth - Investing.com Canada
Pet Wellness Products Market Touching New Development Level | Zoetis, Elanco, Virbac - openPR.com
Analysts Offer Insights on Healthcare Companies: Definitive Healthcare Corp (DH), Elanco Animal Health (ELAN) and Align Tech (ALGN) - The Globe and Mail
Elanco Animal Health Inc (ELAN) Shares Fall 8.2% -- GF Value Says Still Overvalued - GuruFocus
Elanco (ELAN) Q1 earnings: What to expect - MSN
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Elanco Animal Health - TMX Newsfile
Elanco Animal Health Q1 Earnings Call Highlights - MarketBeat
Q1 2026 Elanco Animal Health Inc Earnings Call Transcript - GuruFocus
Q3 2025 Elanco Animal Health Inc Earnings Call Transcript - GuruFocus
Elanco Animal Health Inc Investor Day Transcript - GuruFocus
ELAN SEC FilingsElanco Animal Health 10-K, 10-Q, 8-K Forms - Stock Titan
Elanco (ELAN) shares climb after strong quarterly results and higher full-year outlook - msn.com
MSN Money - MSN
Elanco Animal Health Price Target Raised to $31.00/Share From $30.00 by Citigroup - Moomoo
Elanco Animal Health 1Q Adj EPS 40c >ELAN - Moomoo
ELAN Maintained by Citigroup -- Price Target Raised to $31.00 - GuruFocus
ELAN Maintained by JP Morgan -- Price Target Raised to $30 - GuruFocus
Elanco Earnings Call Highlights Innovation-Led Growth - The Globe and Mail
Finanzdaten der Elanco Animal Health Inc-Aktie (ELAN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.37%
4.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):